Elliot Ehrich, Chief Medical Officer of Alkermes. These results will support a phase 2 clinical study of ALKS 37, that may assess the safety, efficacy and tolerability of ALKS 37 in individuals with OIC. The phase 2 study is expected to begin in the first half of calendar 2010. SOURCE Alkermes, Inc.. Alkermes initiates multidose Stage 1 clinical research of ALKS 37 for OIC Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical research of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly known as opioid-induced constipation . The randomized, double-blind, placebo-controlled, repeat-dose study will measure the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in 24 healthy volunteers approximately.11-14 On the basis of a study involving several consanguineous households in Pakistan,12 the strongest linkage is with a locus on the lengthy arm of chromosome 12. We analyzed this locus in several affected Pakistani families and in a number of affected but unrelated topics from Pakistan, THE UNITED STATES, and Britain, as well as in unaffected, unrelated control topics from both North and Pakistan America. Methods We analyzed family members that had participated in prior linkage research12 and centered on the biggest family, designated PKST72 .